Cambridge Healthtech Institute’s Sixth Annual

Circulating Tumor Cells

Enabling Liquid Biopsy

March 7 – 9, 2016 | Moscone North Convention Center | San Francisco, CA
Part of the 23rd International Molecular Medicine Tri-Conference

 

Many technologies have been developed for the application of circulating tumor cells, including techniques for isolation, enumeration, characterization, propagation and genomic profiling. However, as yet there is only one approved technology for clinical use. This year’s Sixth Annual Circulating Tumor Cells conference will delve into new insights in the field of circulating tumor cell research and clinical application by investigating key challenges for advancement into the clinic. The visionary faculty will look at comparisons of technical progress and advancement for a range of circulating biomarkers including cell-free DNA, exosomes and extracellular vesicles and illuminate strategies for moving them into clinical use.

Preliminary Agenda


LIQUID BIOPSY IN INTERVENTIONAL SETTINGS

Liquid Biopsy: Expectations and Required Steps to Bring It into Clinical Practice

Klaus Pantel, M.D., Professor and Founding Director, Institute of Tumor Biology, University, Medical Center Hamburg-Eppendorf

Talk Title to be Announced

Howard I. Scher, M.D., Chief, Genitourinary Oncology & Solid Tumor Medicine, Memorial Sloan Kettering Cancer Center


THE NEXT THING IN CIRCULATING BIOMARKERS: BEYOND CHARACTERIZATION AND ENUMERATION OF CTCS

FEATURED PRESENTATION: Circulating Pancreas Cells to Stratify Risk in Patients at High Risk for Developing Pancreatic Cancer and RNA Editing Using NGS

Andrew D. Rhim, M.D., Assistant Professor, Internal Medicine, Division of Gastroenterology, University of Michigan

Novel Biomarkers to Increase Efficiency of Detecting CTCs and Associated Immune Cells

Lidia C. Sambucetti, Ph.D., Senior Program Director, Biosciences Division, SRI International

Platelet Cloaking, Cancer Cells and CTCs: Lessons for the Metastatic Cascade

John O'Leary, M.D., Ph.D., Chair, Pathology, Trinity College Dublin; Director, Pathology, Coombe Women and Infants University Hospital; Consultant, Pathologist, St. James’s Hospital; Principal Investigator, Biomedical Diagnostics Institute (BDI)


FUNCTIONAL CTC STUDIES

Detection, Characterization and ex vivo Expansion of Viable Circulating Tumor Cells

Catherine Alix-Panabières, Ph.D., Maître de Conférence - Praticien Hospitalier, Associate Professor, Director, Laboratory of Rare Human Circulating Cells, Institute of University Clinical Research (IURC), University Medical Centre of Montpellier, University of Montpellier

Detection and Molecular Profiling of Single CTCs and a Patient-Derived CTC Line

Tobias M. Gorges, Ph.D., Senior Scientist, Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf

A Direct, Chip-Based Approach to Analysis of Cell-Free Nucleic Acids

Shana Kelley, Ph.D., Professor, Biochemistry, University of Toronto

Isolation and ex vivo Expansion of CTCs for Molecular Diagnosis and Drug Testing

Sunitha Nagrath, Ph.D., Assistant Professor, Chemical Engineering, University of Michigan


MOUSE MODELS FOR TESTING NEW TECHNOLOGY

Circulating Tumor Cells and Mouse Models of Serous Ovarian Cancer

Victoria Bae-Jump, M.D., Ph.D., Associate Professor, Division of Gynecologic Oncology, University of North Carolina

Orthotopic Mouse Models of Cancer and GFP Labeling for the Study of Circulating Tumor Cells

Robert M. Hoffman, Ph.D., President, AntiCancer, Inc.; Professor, Surgery, University of California, San Diego


NEW TECHNOLOGIES

Early Pancreatic Markers, Biomarkers for Exosome Isolation

Raghu Kalluri, M.D., Ph.D., Professor & Chair, Cancer Biology, MD Anderson Cancer Center

KEYNOTE PRESENTATION:
Isolating Circulating Biomarkers: Compare and Contrast cfDNA, CTCs and Exosomes

Steven A. Soper, Ph.D., Professor, Biomedical Engineering & Chemistry; Associate Editor, Analyst; Director, Center for BioModular Multiscale Systems, University of North Carolina

Why Do Cancer Cells Move?

Daniel Irimia, M.D., Ph.D., Assistant Professor, Division of Surgery, Science & Bioengineering, Massachusetts General Hospital and Harvard Medical School; Associate Director, BioMEMS Resource Center

Extracellular Vesicles as Couriers of Cancer Information

Xandra O. Breakefield, Ph.D., Professor, Neurology, Harvard Medical School; Geneticist, Department of Neurology and Radiology, Massachusetts General Hospital

PANEL DISCUSSION

How Do We Get Penetration of New CTC Technology into the Marketplace?

The NCI SBIR/STTR Program: Accelerating the Commercialization of New CTC Technologies

Xing-Jian Lou, Ph.D, Program Director, SBIR Development Center, National Cancer Institute

PANEL DISCUSSION

Steven A. Soper, Ph.D., Professor, Biomedical Engineering & Chemistry; Associate Editor, Analyst; Director, Center for BioModular Multiscale Systems, University of North Carolina
Murali Prahalad, Ph.D., President & CEO, Epic Sciences
Hsian-Rong Tseng, Ph.D., Professor, Molecular & Medical Pharmacology; Member, JCCC Cancer Molecular Imaging; Faculty, Crump Institute for Molecular Imaging, University of California, Los Angeles


PROPAGATING CELLS: CTCS AS EARLY GUIDE FOR TREATMENT RESPONSE PRIOR TO IMAGING

Tumorigenicity and Genetic Profiling of Circulating Tumor Cells in Small-Cell Lung Cancer

Kristopher Frese, Ph.D., Postdoctoral Fellow, University of Manchester

Antibody-Free Capture of Tumor Cells from Blood and Novel CTC-Targeting Therapeutics

Michael R. King, Ph.D., Daljit S. and Elaine Sarkaria Professor of Biomedical Engineering, Meinig School of Biomedical Engineering, Cornell University

Conditional Reprogramming Rapidly and Efficiently Generates Normal and Tumor Cell Cultures

Richard Schlegel, M.D., Ph.D., Professor and Oscar B. Hunter Chair, Pathology; Director, Center for Cell Reprogramming, Georgetown University Medical School

Premier Sponsors:  

Bina Technologies

Coyote

Elsevier   

Jackson Laboratory - small logo 

 NanoString2   

 Precision for Medicine 

SeraCare(2)

Silicon Biosystems

Thomson Reuters-Large